Default company panoramic image

AbCelex Technologies Inc.

AbCelex is a biotechnology company addressing unmet needs in multi-billion dollar food animal health and diagnostics.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded November 2010
  • Employees 4
  • Website

Company Summary

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies and products for improving the health of food animals in order to increase food safety and production performance. Our diagnostic line of products allows for early, accurate and cost-effective detection of various diseases in food animal as well as human health.


  • Default avatar
    Saeid Babaei
    President & CEO

    Over 15 years of global business experience where he has negotiated several strategic alliances and licensing deals, established joint ventures and assisted in private financings to support product development.

    Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. He currently serves as a member of Board of Director

  • Default avatar
    Ali Riazi

    Brings to AbCelex extensive experience in molecular biology and antibody design and engineering. At AbCelex, Dr. Riazi is responsible for all scientific operations of the Company including establishing and managing various R&D collaborations and strategic partnerships. Prior to joining AbCelex, Dr. Riazi was heading a team of scientists engaged in elucidating molecular mechanisms of cardiovascular disease at the Hospital for Sick Children.

  • Default avatar
    Paul Dick
    Board Member

    - Over 20 years of experience with increasing responsibility with two multinational pharmaceuticals including COO of Naturagen Health Solutions, within Elanco, a division of Eli Lilly and Company (NYSE:LLY).
    - CEO of Chemaphor, involved in development of pharmaceuticals and veterinary natural health products.
    - Holds a veterinary degree with advanced training in infectious diseases and immunology.

  • Default avatar
    Peter Mandl
    VP, Corporate Development

    With more than 20 years industry experience, Mr. Mandl is a seasoned technology and business leader. He has a proven record driving innovation, executing on strategic plans and delivering results. With both large and small company experience, Mr. Mandl was a key contributor to several start-ups including a successful IPO at Genesis Microchip Inc. His diverse background includes sales, marketing, finance, product management, contracts, IP licens


  • Default avatar
    Shahrooz Nabavi @ Fasken Martineau DuMoulin LLP
    Default avatar
    John P. Seychuk, CA